

---

**Operations Office**

Telephone (507) 266-3549

---



**Date:** May 20, 2005

**To:** NCCTG Members

**From:** Lori K. Kelly  
Protocol Development Coordinator

**Re:** N0177, A Phase I/II Study of OSI-774 and Temozolomide in Combination with Radiation Therapy in Glioblastoma Multiforme

Due to Study 3 opening to non-EIAC patients effective May 20, 2005, the attached eligibility checklist has been revised to reflect the closing of Study 1 and the opening of Study 3, therefore the eligibility checklist will read Study 2 or 3 rather than Study 1 and 2. Please replace your current version of the checklist with this revised version.

**PLEASE NOTE:** With the closing of Study 1 and the opening of Study 3, an addendum to the protocol will be forthcoming.

If you have any questions concerning this communication, please contact me at 507/266-3549.

Thank you.

Lkk  
enclosure